← Back to Investor Relations
In the Press
Helio Genomics Mulls New AI-Driven Dx Opportunities While Readying Liver Cancer Test for US
Why This Matters
Precision Medicine Online is a highly targeted publication for precision oncology professionals, molecular diagnostics researchers, and clinical lab directors — exactly the clinical and scientific audience that validates and drives adoption of new diagnostic technologies.
Article Summary
Precision Medicine Online reports on Helio Genomics exploring new AI-driven diagnostic opportunities beyond liver cancer while preparing HelioLiver for broader US availability through Quest Diagnostics. The article suggests Helio is positioning its multi-analyte AI platform as a foundation for expanding into additional cancer types, signaling a broader pipeline strategy.